



We Treat Kids Better

Michael Pulsipher, MD  
Professor of Pediatrics,  
Section Head BMT,  
Endowed Chair, BMT Clinical Research

Sonata Jodele, MD  
Professor of Pediatrics,  
Clinical Director

Neena Kapoor, MD  
Professor of Pediatrics,  
Director BMT

Hisham M. Abdel-Azim, MD  
Associate Professor of Pediatrics,  
Co-Director BMT Laboratory  
Director FACS Laboratory

Agne Taraseviciute, MD, PhD  
Assistant Professor,  
Clinical Pediatrics

Moghim Babak, MD  
Assistant Professor of Pediatrics

**Advanced Practitioners**  
Chelsea Balian, CPNP  
Dorothy Dokko, CPNP-AC  
Michelle Garcia, CPNP  
Jonelle Gray, CPNP, CPHON  
Rebecca Kaviani, PA-C  
Andrea Tizano, CPNP, CPHON  
Vivian Wu, CPNP

**Hospitalists**  
Lauren Ferreros, MD  
Melody Hsu, MD  
Kim Minhee, MD  
Re Zaw, MD

**Transplant Nurse Coordinators**  
Deborah Marino, RN, CPON  
Kim Miner, RN  
Shinyi Tang, PNP, RN, CPON  
Laura Vasquez, RN, CPON

**Regulatory/Quality**  
Rafael Bravo Lopez  
Angelie Narvaez  
Alfonso Parra  
Veronica Terrones-Hudson

**BMT Laboratory**  
Julie Annis, MLS(ASCP)<sup>CM</sup>  
Jennifer Tam

**Research Coordination**  
Renna Killen  
Arieli Kimberly  
Anju Nair  
Sandy Tran  
Anusha Williamson

**Social Workers**  
Jennifer Reyes, LCSW, ACM-SW, OSW-C  
Talya Schlesinger, MSW

**Administrative Support**  
Robert Torres  
Elsa Veliz  
Michelle Fernandez

Phone: Patients/Referrals-323.361.2546  
Admin Office-323.361.1489/4559

February 12, 2019

John Thomas, PhD, JD  
Chair, Governing Board of the CIRM (ICOC)  
210 King Street  
San Francisco, CA 94107

Re: CLIN2-11431: A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants

Dear Dr. Thomas,


My name is Neena Kapoor. I am Director of Blood and marrow and cell therapy laboratory and attending physician of Blood and Marrow transplant and Cell therapy program at Children's Hospital Los Angeles and professor of Pediatrics at Keck school of Medicine at USC.

I am a Blood and Marrow stem cell transplanter with special interest in Primary immunodeficiency diseases and alternative donor stem cell transplants especially for severe combined immune-deficiency disorders. Over the years, the field has evolved from performing transplants from matched sibling donors to Haploidentical donors after T cell depletion, to unrelated donors. We have learnt the need for conditioning regimen for such transplants and issues associated with the pre transplant conditioning. It is utmost important for us to now address how can we now move to next step of abating the acute and chronic toxicities associated with conditioning regimen, without compromising engraftment of donor cells and complete reconstitution of immune system. The CIRM-sponsored study referenced.

Above, is based on use of a monoclonal antibody directed against CD117, represents the opportunity to deplete autologous hematopoietic stem cells without causing unwanted toxicity. I understand the early data gathered so far indicate that this approach is safe. It has been reported to be effective in depleting autologous stem cells while allowing engraftment of donor-derived hematopoietic stem cells. In the future, this may be applicable to treat other genetic diseases also. Continuation of this trial is extremely important to confirm efficacy without the unwanted and unnecessary toxicity associated with standard conditioning regimen. If proven, it will have wider application in the field of transplantation.

Thank you for your consideration,  
Sincerely,

**Neena Kapoor, MD**

Director, Blood and Marrow Transplant Laboratory  
Professor of Pediatrics, Keck School of Medicine, USC  
*Hematology, Oncology and Blood & Marrow Transplantation*  
Children's Hospital Los Angeles   
4650 Sunset Blvd., Mailstop #54 | Los Angeles, CA 90027  
Ph: 323.361.2434 | Fax: 323.361.8068 | nkapoor@chla.usc.edu